Efficacy and outcome of Tofacitinib in Immune checkpoint inhibitor colitis.
暂无分享,去创建一个
P. Higgins | L. Fecher | W. Sharfman | C. Lao | S. Bishu | J. Melia
[1] M. Hudson,et al. Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. , 2020, The New England journal of medicine.
[2] M. Suarez‐Almazor,et al. Immune-related adverse events of checkpoint inhibitors , 2020, Nature Reviews Disease Primers.
[3] Douglas B. Johnson,et al. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Charabaty,et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study , 2018, Journal of Immunotherapy for Cancer.
[5] B. Helmink,et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis , 2018, Nature Medicine.
[6] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[7] T. Graeber,et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.
[8] J. Wolchok,et al. Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.